ReviewAntioxidants (Basel, Switzerland)2026
PRDX1 as a Redox Gatekeeper at Mitochondrial-ER Contact Sites: Implications for Kidney Fibrosis Progression and Therapy.
Review in Antioxidants (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Peroxiredoxins (PRDXs) constitute a class of thiol-dependent oxidoreductive regulatory factors whose functions extend beyond peroxide detoxification to include the regulation of oxidoreductive signaling, organelle homeostasis, and cell fate determination. The emerging role of PRDX1-6 in fibrotic diseases-particularly PRDX1's function as an oxidoreductive signaling modulator dependent on specific pathological contexts during renal injury and fibrosis-calls for further investigation. We propose a dual-regulatory model in which PRDX1 simultaneously governs both the mitochondrial reactive oxygen species (ROS)-JNK/Smad signaling pathway and the endoplasmic reticulum (ER) stress-protein kinase R-like endoplasmic reticulum kinase (PERK)/eukaryotic initiation factor 2α (eIF2α)/activating transcription factor 4 (ATF4)/C/EBP homologous protein (CHOP)-gasdermin E (GSDME) signaling pathway, thereby linking organelle oxidoreductive imbalance to epithelial cell injury, inflammatory cell death, and fibrotic remodeling. Notably, we hypothesize that the mitochondria-associated membranes (MAMs) serve as a critical spatial interface for the convergence of these signaling pathways. At the MAMs, PRDX1 may function as an "oxidoreductive gatekeeper," buffering local peroxide signaling while coordinating the oxidoreductive balance, Ca
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.